Castle Biosciences Inc (CSTL)vsIDEXX Laboratories Inc (IDXX)
CSTL
Castle Biosciences Inc
$19.83
+3.07%
HEALTHCARE · Cap: $583.55M
IDXX
IDEXX Laboratories Inc
$560.11
-2.11%
HEALTHCARE · Cap: $45.14B
Smart Verdict
WallStSmart Research — data-driven comparison
IDEXX Laboratories Inc generates 1192% more annual revenue ($4.45B vs $344.23M). IDXX leads profitability with a 24.6% profit margin vs -7.0%. IDXX earns a higher WallStSmart Score of 63/100 (C+).
CSTL
Avoid33
out of 100
Grade: F
IDXX
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+65.9%
Fair Value
$94.72
Current Price
$19.83
$74.89 discount
Margin of Safety
-41.2%
Fair Value
$459.52
Current Price
$560.11
$100.59 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Every $100 of equity generates 73 in profit
Strong operational efficiency at 31.8%
Keeps 25 of every $100 in revenue as profit
Areas to Watch
0.8% revenue growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -5.2% — below average capital efficiency
Expensive relative to growth rate
Premium valuation, high expectations priced in
Trading at 27.8x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : CSTL
The strongest argument for CSTL centers on Price/Book, Debt/Equity, Altman Z-Score.
Bull Case : IDXX
The strongest argument for IDXX centers on Return on Equity, Operating Margin, Profit Margin. Profitability is solid with margins at 24.6% and operating margin at 31.8%. Revenue growth of 14.3% demonstrates continued momentum.
Bear Case : CSTL
The primary concerns for CSTL are Revenue Growth, Market Cap, Piotroski F-Score.
Bear Case : IDXX
The primary concerns for IDXX are PEG Ratio, P/E Ratio, Price/Book. A P/E of 42.0x leaves little room for execution misses.
Key Dynamics to Monitor
CSTL profiles as a turnaround stock while IDXX is a mature play — different risk/reward profiles.
IDXX carries more volatility with a beta of 1.57 — expect wider price swings.
IDXX is growing revenue faster at 14.3% — sustainability is the question.
IDXX generates stronger free cash flow (232M), providing more financial flexibility.
Bottom Line
IDXX scores higher overall (63/100 vs 33/100), backed by strong 24.6% margins and 14.3% revenue growth. CSTL offers better value entry with a 65.9% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Castle Biosciences Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Castle Biosciences Inc. is a cutting-edge diagnostics company dedicated to transforming patient care through its innovative gene-expression profiling tests, particularly in the realm of skin cancer. Its flagship product, DecisionDx®-Melanoma, is instrumental in the management of melanoma, providing critical insights into patient risk stratification and treatment decision-making. With a robust commitment to precision medicine, Castle is actively expanding its portfolio of assays to address unmet clinical needs. Bolstered by a strong research and development focus and an ambitious pipeline, the company is strategically positioned for sustainable growth while enhancing clinical outcomes and delivering significant value to its shareholders in the evolving oncology marketplace.
Visit Website →IDEXX Laboratories Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?